Weiting Liao

Dr. Weiting Liao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAntonio Cigliano
Antonio Cigliano
WLWeiting Liao
Weiting Liao
GDGiovanni A. Deiana
Giovanni A. Deiana
DRDavide Rizzo
Davide Rizzo
XCXin Chen
Xin Chen
DCDiego Francesco Calvisi
Diego Francesco Calvisi
Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years. In addition to the traditional chemically and dietary-induced HCC models, a broad spectrum of novel preclinical tools have been generated following the advent of transgenic, transposon, organoid, and in silico technologies to overcome this gloomy scenario. These models have become rapidly robust preclinical instruments to unravel the molecular pathogenesis of liver cancer and establish new therapeutic approaches against this deadly disease. The present review article aims to summarize and discuss the commonly used preclinical models for HCC, evaluating their strengths and weaknesses.

29 December 2022 in Cancer Medicine
Verified
Journal Article
Open access
WLWeiting Liao
Weiting Liao
YYYu Yang
Yu Yang
HYHuazhen Yang
Huazhen Yang
YQYuanyuan Qu
Yuanyuan Qu
HSHuanlu Song
Huanlu Song
QLQiu Li
Qiu Li
Background: To determine whether serum gamma‐glutamyl transpeptidase (GGT) level is associated with pancreatic cancer risk in a large prospective cohort.Methods: The study analyzed serum GGT concentration at baseline of 421,032 participants recruited in the UK Biobank since 2006 through 2010. Information on incidence of pancreatic cancer was obtained from cancer and death registers, updated until 2015 in Scotland or 2016 in England and Wales. Adjusted Cox proportional hazards models were used to measure the association between serum GGT and pancreatic cancer risk.Results: The study identified 586 cases of pancreatic cancer over a median follow‐up period of 7.16 years. In the multivariable‐adjusted Cox model, serum GGT level was associated with 14% higher pancreatic cancer risk (hazard ratio (HR) per one standard deviation increment of log2 GGT level = 1.14, 95% confidence interval (CI) 1.02–1.28, p = 0.025). In the total population, the HR for the highest GGT group was 1.68 (95%CI: 1.22–2.30) versus the lowest GGT group. The HR for the highest GGT group in men (≥50.2 U/L) was 1.72 (95%CI: 1.14–2.61) and that in women (≥31.6 U/L) was 1.75 (95%CI: 1.06–2.88) versus the lowest GGT group.Conclusion: Our findings suggested a positive association of serum GGT in pancreatic cancer etiology, implying the potential of monitoring GGT level for identifying at‐risk individuals for pancreatic cancer.

27 February 2023 in Hepatology Communications
Verified
Journal Article
Open access
WLWeiting Liao
Weiting Liao
DCDiego Francesco Calvisi
Diego Francesco Calvisi
XCXin Chen
Xin Chen

12 September 2025 in Cancer Research
Verified
Journal Article
Closed access
GCGuofei Cui
Guofei Cui
YZYi Zhou
Yi Zhou
WLWeiting Liao
Weiting Liao
ECEleonora Cossu
Eleonora Cossu
MEMatthias Evert
Matthias Evert
XWXue Wang
Xue Wang
Aberrant activation of AKT is a key oncogenic driver in hepatocellular carcinoma (HCC). As AKT activates multiple downstream signaling pathways, the key mechanisms mediating AKT-driven tumorigenesis must be elucidated to develop optimal treatment strategies. Using an Akt/NRas-induced HCC mouse model, we found that AKT promotes tumorigenesis by targeting tuberous sclerosis complex 2 (TSC2) and glycogen synthase kinase 3 α/β (GSK3α/β) rather than forkhead box O protein family members. Loss of either TSC2, leading to mTORC1 activation, or both GSK3 isoforms cooperated with activated NRAS to promote HCC formation in vivo, albeit with different latencies. Simultaneous TSC2 and GSK3α/β deletion cooperated with NRAS to rapidly induce HCC formation, mirroring observations from the Akt/NRas HCC model. RNA sequencing studies indicated distinct pathways regulated by TSC2/mTORC1 and GSK3α/β during hepatocarcinogenesis, with FOXM1 functioning as a major effector of GSK3. In summary, these findings uncover AKT’s role in suppressing the TSC complex and GSK3 to drive HCC, offering mechanistic insights into oncogenic signaling and potential therapeutic targets. Significance: GSK3α/β and TSC2/mTORC1 are key downstream effectors of AKT in liver tumorigenesis that can potentially be targeted to benefit patients with hepatocellular carcinoma harboring aberrantly activated AKT.

25 February 2025 in Hepatology
Verified
Journal Article
Closed access
WLWeiting Liao
Weiting Liao
YZYi Zhang
Yi Zhang
JWJingxiao Wang
Jingxiao Wang
GCGuofei Cui
Guofei Cui
MEMatthias Evert
Matthias Evert
XCXin Chen
Xin Chen
Background & aims: Hepatoblastoma (HB) is the predominant primary malignant liver tumor in childhood. Concomitant YAP and β-Catenin activation occurs in most HB. However, the signaling pathways distinctively regulated by YAP and β-Catenin protooncogenes in HB remain unexplored. Approach and results: We engineered an inducible HB murine model using hydrodynamic injection to deliver transposon plasmids encoding constitutive YAP and doxycycline (Dox)-inducible ΔN90-β-Catenin(YAP/TRE-β-Catenin). Gene expression patterns in mouse HB lesions upon short-term Dox withdrawal, i.e., tumors still existed, but ΔN90-β-Catenin was turned OFF, were analyzed. Mice rapidly developed aggressive HB lesions when fed doxycycline. However, upon Dox withdrawal, HB regressed, although tumors did not completely disappear over a long time. At the molecular level, YAP and β-Catenin were found to regulate distinct gene expression programs in HB. Specifically, YAP controls the Hippo and metabolism-related pathways, whereas β-Catenin modulates immune-related pathways contributing to immune exclusion in the tumor microenvironment. Furthermore, we identified the transcription factor ONECUT1 as a tumor suppressor gene downregulated by activated β-Catenin in HB. Low ONECUT1 expression also characterizes human HB, and co-expression of ONECUT1 strongly suppressed YAP/β-Catenin-driven HB formation in mice. Mechanistically, ONECUT1 functions downstream of activated β-Catenin and negatively regulates tumor cell glycolysis. Conclusions: We show that suppressing activated β-Catenin could hamper HB progression in vivo by affecting pathways distinct from those regulated by YAP in HB. Inhibition of ONECUT1 expression by β-Catenin might represent a critical molecular event leading to HB formation. Export

15 December 2025
Verified
Other
Open access
GCGuofei Cui
Guofei Cui
YZYi Zhou
Yi Zhou
WLWeiting Liao
Weiting Liao
ECEleonora Cossu
Eleonora Cossu
MEMatthias Evert
Matthias Evert
XWXue Wang
Xue Wang
Aberrant activation of AKT is a key oncogenic driver in hepatocellular carcinoma (HCC). As AKT activates multiple downstream signaling pathways, the key mechanisms mediating AKT-driven tumorigenesis must be elucidated to develop optimal treatment strategies. Using an Akt/NRas-induced HCC mouse model, we found that AKT promotes tumorigenesis by targeting tuberous sclerosis complex 2 (TSC2) and glycogen synthase kinase 3 α/β (GSK3α/β) rather than forkhead box O protein family members. Loss of either TSC2, leading to mTORC1 activation, or both GSK3 isoforms cooperated with activated NRAS to promote HCC formation in vivo, albeit with different latencies. Simultaneous TSC2 and GSK3α/β deletion cooperated with NRAS to rapidly induce HCC formation, mirroring observations from the Akt/NRas HCC model. RNA sequencing studies indicated distinct pathways regulated by TSC2/mTORC1 and GSK3α/β during hepatocarcinogenesis, with FOXM1 functioning as a major effector of GSK3. In summary, these findings uncover AKT’s role in suppressing the TSC complex and GSK3 to drive HCC, offering mechanistic insights into oncogenic signaling and potential therapeutic targets.Significance:GSK3α/β and TSC2/mTORC1 are key downstream effectors of AKT in liver tumorigenesis that can potentially be targeted to benefit patients with hepatocellular carcinoma harboring aberrantly activated AKT.